Celularity Inc.
Investor Relations
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (MLASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Latest Press Releases
Events & Presentations
A Fully Integrated Cellular and Regenerative Medicine Company – Celularity Investor Presentation February 2025
Feb 20, 2025, at 7:48 pm ET
HC Wainwright Conference Presentation, September 9, 2024
Sep 9, 2024, at 3:30 pm EST
Abstract 2554: Placental Circulating T Cells Expressing CD16 Demonstrate Potent Efficacy Against Multiple Hematological and Solid Tumor
Cancers Through Combination with Various Monoclonal Antibodies
May 31, 2024, at 12:01 pm ET
Celularity Research & Development Day Presentation – May 2024
May 21, 2024, at 6:36pm EST
AACR 2024 Abstract #5232 – Placental Circulating T Cells Expressing CD16 in Combination with Trastuzumab Demonstrate Robust Anti-tumor Antibody-dependent Cellular Cytotoxicity (ADCC) Against Gastric Cancer
April 10, 2024, at 3:13 pm ET
Celularity Investor Presentation
Last Updated June, 2022
Jefferies Cell and Genetic Medicine Summit
September 30, 2022, at 11:00 am ET
Celularity at Morgan Stanley 20th Annual Global Healthcare Conference
September 14, 2022, at 12:20 pm ET
Celularity at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022, at 1:30 pm ET
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products